Why is Novartis’ del-desiran failure raising scrutiny of a $12 billion deal?

BioPharma Dive reported that Novartis’ RNA drug del-desiran fell short in a study in a rare muscle disease, and the asset came through a $12 billion acquisition. The miss is prompting questions about whether Novartis’ deal thesis, capital allocation, and business development judgment on the broader RNA portfolio still hold up.